Skip to content
DataLookout
Menu

NCT07930624

A Study to Investigate Long-term Safety and Tolerability of Frexalimab in Participants With Multiple Sclerosis

StatusNot Yet Recruiting
PhasePhase 3
SponsorSanofi
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Number of participants with Adverse Events(AEs)
Timeframe: up to to approximately 2.5 years since last participant in

Secondary (9)

Participants from EFC17919A, EFC17919B, and EFC17504 studies only: time to onset of 6-month composite confirmed disability worsening(cCDW) for RMS or composite confirmed disability progression(cCDP) for nrSPMS
Time to onset of individual components of the composite, confirmed over 3 months or 6 months EDSS for all prior study participants 9-HPT, T25FW test (participants rolling over from EFC17504, EFC17919A, and EFC17919B)
Progression independent of relapse activity defined as the time to onset of 6-month cCDW
Number of new and/or enlarging T2-hyperintense lesions per year as detected by MRI
Total number of new GdE T1 lesions per year as detected by MRI
Show 4 moreShow less
Change from baseline at scheduled visits in total volume of T2-hyperintense lesions as detected by brain MRI
ARR assessed by confirmed protocol defined relapses
antidrug antibodys(ADAs) incidence
Change from baseline in serum immunoglobulin(Ig) levels

Arms and interventions

Frexalimab SC (OL)Experimental

Participants will be administered frexalimab subcutaneous

Frexalimab IV (OL)Experimental

Participants will be administered frexalimab intravenously

Frexalimab (DB)Experimental

For EFC17919A/B parent study participants: at Opt-in visit participants will continue to be administered f rexalimab through unblinding visit. Participants will receive placebo tablet once daily until the unblinding visit.

Teriflunomide (DB)Active comparator

For EFC17919A/B parent study participants: at Opt-in visit participants will continue to receive teriflunomide tablet. The placebo will be administered to participants at the same infusion rate and duration as for frexalimab from the opt-in visit until availability of results and unblinding.

Drugs: Frexalimab, Frexalimab Placebo, Teriflunomide, Teriflunomide Placebo, MRI contrast-enhancing agents, Cholestyramine, charcoal